vs
Side-by-side financial comparison of AETHLON MEDICAL INC (AEMD) and ANGIODYNAMICS INC (ANGO). Click either name above to swap in a different company.
ANGIODYNAMICS INC is the larger business by last-quarter revenue ($79.4M vs $60.0K, roughly 1324.7× AETHLON MEDICAL INC). ANGIODYNAMICS INC runs the higher net margin — -8.0% vs -2926.4%, a 2918.4% gap on every dollar of revenue. ANGIODYNAMICS INC produced more free cash flow last quarter ($4.2M vs $-2.0M).
Aethlon Medical Inc. is a clinical-stage medical technology firm that develops targeted therapeutic devices to address life-threatening health conditions. Its lead product, the Hemopurifier, is designed to remove harmful viruses, cancer-derived exosomes, and other pathogens from the bloodstream. The company primarily operates in the infectious disease and oncology healthcare segments, with main market presence in North America.
AngioDynamics Inc is a global medical technology firm that designs, manufactures and sells a portfolio of minimally invasive medical devices. Its core offerings cover vascular access, surgical ablation, and oncology care solutions, serving hospitals, outpatient surgery centers and other healthcare providers across North America, Europe and Asia Pacific.
AEMD vs ANGO — Head-to-Head
Income Statement — Q3 2025 vs Q2 2026
| Metric | | |
|---|---|---|
| Revenue | $60.0K | $79.4M |
| Net Profit | $-1.8M | $-6.3M |
| Gross Margin | — | 56.4% |
| Operating Margin | -3026.4% | -7.7% |
| Net Margin | -2926.4% | -8.0% |
| Revenue YoY | — | 9.0% |
| Net Profit YoY | 49.4% | 40.9% |
| EPS (diluted) | $-10.05 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $79.4M | ||
| Q3 25 | — | $75.7M | ||
| Q2 25 | — | $80.2M | ||
| Q1 25 | — | $72.0M | ||
| Q4 24 | $60.0K | $72.8M | ||
| Q3 24 | $95.1K | $67.5M | ||
| Q2 24 | — | $71.0M | ||
| Q1 24 | — | $75.2M |
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-10.9M | ||
| Q2 25 | — | $-6.0M | ||
| Q1 25 | — | $-4.4M | ||
| Q4 24 | $-1.8M | $-10.7M | ||
| Q3 24 | $-2.8M | $-12.8M | ||
| Q2 24 | — | $-13.4M | ||
| Q1 24 | — | $-187.7M |
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 52.7% | ||
| Q1 25 | — | 54.0% | ||
| Q4 24 | — | 54.8% | ||
| Q3 24 | — | 54.4% | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | — | -7.7% | ||
| Q3 25 | — | -14.1% | ||
| Q2 25 | — | -7.2% | ||
| Q1 25 | — | -13.9% | ||
| Q4 24 | -3026.4% | -15.2% | ||
| Q3 24 | -3050.2% | -19.4% | ||
| Q2 24 | — | -20.4% | ||
| Q1 24 | — | -265.9% |
| Q4 25 | — | -8.0% | ||
| Q3 25 | — | -14.4% | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | -2926.4% | -14.7% | ||
| Q3 24 | -2950.2% | -19.0% | ||
| Q2 24 | — | -18.9% | ||
| Q1 24 | — | -249.7% |
| Q4 25 | — | $-0.15 | ||
| Q3 25 | — | $-0.26 | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | $-10.05 | $-0.26 | ||
| Q3 24 | $-16.11 | $-0.31 | ||
| Q2 24 | — | $-0.35 | ||
| Q1 24 | — | $-4.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.8M | $41.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.3M | $176.3M |
| Total Assets | $6.5M | $269.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $41.6M | ||
| Q3 25 | — | $38.8M | ||
| Q2 25 | — | $55.9M | ||
| Q1 25 | — | $44.8M | ||
| Q4 24 | $4.8M | $54.1M | ||
| Q3 24 | $6.9M | $55.0M | ||
| Q2 24 | — | $76.1M | ||
| Q1 24 | — | $78.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | — |
| Q4 25 | — | $176.3M | ||
| Q3 25 | — | $178.9M | ||
| Q2 25 | — | $183.0M | ||
| Q1 25 | — | $185.9M | ||
| Q4 24 | $4.3M | $186.8M | ||
| Q3 24 | $6.0M | $196.6M | ||
| Q2 24 | — | $205.6M | ||
| Q1 24 | — | $218.7M |
| Q4 25 | — | $269.7M | ||
| Q3 25 | — | $265.6M | ||
| Q2 25 | — | $280.1M | ||
| Q1 25 | — | $285.4M | ||
| Q4 24 | $6.5M | $291.6M | ||
| Q3 24 | $8.8M | $293.6M | ||
| Q2 24 | — | $317.7M | ||
| Q1 24 | — | $324.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $4.7M |
| Free Cash FlowOCF − Capex | $-2.0M | $4.2M |
| FCF MarginFCF / Revenue | -3357.0% | 5.3% |
| Capex IntensityCapex / Revenue | 3.7% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-9.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.7M | ||
| Q3 25 | — | $-15.9M | ||
| Q2 25 | — | $18.8M | ||
| Q1 25 | — | $-13.2M | ||
| Q4 24 | $-2.0M | $2.5M | ||
| Q3 24 | $-2.2M | $-18.3M | ||
| Q2 24 | — | $5.0M | ||
| Q1 24 | — | $-12.5M |
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $-16.6M | ||
| Q2 25 | — | $18.0M | ||
| Q1 25 | — | $-15.0M | ||
| Q4 24 | $-2.0M | $1.7M | ||
| Q3 24 | — | $-19.3M | ||
| Q2 24 | — | $4.4M | ||
| Q1 24 | — | $-13.1M |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | -22.0% | ||
| Q2 25 | — | 22.5% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | -3357.0% | 2.3% | ||
| Q3 24 | — | -28.7% | ||
| Q2 24 | — | 6.2% | ||
| Q1 24 | — | -17.5% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | 3.7% | 1.1% | ||
| Q3 24 | 0.0% | 1.6% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 0.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AEMD
Segment breakdown not available.
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
